Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182845-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$79.90
|
|
|
Ab182845-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$359.90
|
|
|
Ab182845-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$889.90
|
|
|
Ab182845-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,429.90
|
|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level < 0.01EU/μg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Orilanolimab (anti-FcRn (FCGRT&B2M)) - Primary antibody, specific to FCGRT & B2M, Human IgG4SP |
|---|---|
| Synonyms | Alpha chain antibody | Fc fragment of IgG, receptor transporter, alpha antibody | FCGRN_HUMAN antibody | FCGRT antibody | FcRn alpha chain antibody | FcRn antibody | FCRN, alpha chain antibody | IgG Fc fragment receptor transporter alpha chain antibody | |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | FCGRT & B2M |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Orilanolimab (anti-FcRn (FCGRT & B2M)) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab (anti-FcRn (FCGRT & B2M)) blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab (anti-FcRn (FCGRT & B2M)) impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab (anti-FcRn (FCGRT & B2M)) disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
|
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 144.6 kDa |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845) - Flow Cytometry
Flow Cytometry analysis of U937 cells labelling FcRn (FCGRT&B2M) (red) with Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845) - ELISA
Immobilized Human FcRn/FCGRT&B2M Heterodimer protein, His and Avi tag at 2.0 μg/mL can bind Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845) with the EC50 of 15.67 ng/mL.
Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845) - SEC
The purity of Orilanolimab (anti-FcRn (FCGRT&B2M)) (Ab182845) is more than 95% verified by HPLC.